Subscribe to Newsletter

Discovery & Development

Discovery & Development Drug Discovery

T Cells, Sea Shells and Cancer Cures

| 5 min read

Adrian Baez-Ortega shares on pioneering the genome sequencing of transmissible cancers in cockles – and what this research means for humans.

Discovery & Development Drug Delivery

Taking Vaccines Beyond Borders

| Jamie Irvine | 3 min read

Can yeast-based vaccines help overcome global vaccine inequity challenges?

Discovery & Development Drug Discovery

Pharma’s Portal to the Lab of the Future

| Becky Upton | 4 min read

Labs of the future will use VR, AR, AI and more. But we must overcome the barriers of implementation, including cultural resistance.

Discovery & Development Drug Discovery

Release the Beast

| Pandora Pound | 5 min read

The FDA Modernization Act opens the door for more innovative alternatives to animal testing for drug discovery and development

Discovery & Development Drug Discovery

Addressing Epilepsy

| Stefanie Dedeurwaerdere | 4 min read

The challenges of complex disorders require collaboration, embracing technological developments, and acknowledging the gaps in access to medicine

Discovery & Development Drug Delivery

At First Sight

| Jamie Irvine | 13 min read

Three companies – Cardinal Health, REGENXBIO, and Beacon Therapeutics – help us explore gene therapy development in the ophthalmic space

Discovery & Development Clinical Trials

Clinical Trials 4.0

| 4 min read

Clinical trials are ripe for improvement; here’s how centralized study information can help

Discovery & Development Drug Discovery

Humans and Machines: Exploring the Reaches of Chemical Space

| Ryan Walsh, Ying Zhang | 6 min read

Machine learning has significant promise, but we should never overlook the importance of the human factor.

Discovery & Development Drug Delivery

MIA and Potent Plants

| Jamie Irvine | 2 min read

Can genetically engineering yeast be used to produce safe and scalable schizophrenia plant-inspired drugs?

Discovery & Development Drug Delivery

Bringing a New MOA to the Table

| Jamie Irvine | 3 min read

Cerevel Therapeutics' Emraclidine - in development for schizophrenia and Alzheimer’s disease psychosis - yields positive results in phase Ib trial

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register